The UroLift implant is designed to treat lower urinary tract symptoms from benign prostatic hyperplasia. Wayne, Pa.-based Teleflex paid $1 billion to acquire NeoTract, which developed UroLift, in October 2017.
The 1,413-patient retrospective study was designed to evaluate UroLift’s safety and effectiveness in a real-world setting, measuring International Prostate Symptom and Quality of Life scores through two years. Results were published in the Journal of Endourology.
Symptoms improved “significantly” at all follow-up points, with mostly mild to moderate peri-operative adverse events that resolved within four weeks, the company said. There were 165 patients in retention at baseline, with 83% catheter-free at one month and 87% catheter-free at two years, with similar IPSS scores to non-retention patients. Of 73 patients who were previously treated for prostate cancer, mean IPSS improved at all follow-ups with no significant differences in adverse events. And IPSS improvement was similar across prostate volumes, Teleflex said.
“Not only are the real-world results from this large, multi-center study consistent with the LIFT study, this study also provides data in the populations of patients who were not studied in the LIFT study but are seen in a real-world clinic setting,” lead investigator and co-author Dr. Gregg Eure said in a press release. “These findings should give urologists and patients the confidence to adopt the UroLift System within the broader BPH population.”
“With over 100,000 men treated worldwide, the UroLift System has become an accepted standard of care treatment for BPH that provides patients rapid symptom relief and recovery,” added interventional urology president Dave Amerson. “We are pleased that these highly positive results continue to demonstrate that outcomes found in a real-world setting are consistent with those in the pivotal LIFT study, and also highlight the effectiveness and versatility of the UroLift System treatment for BPH in diverse patient populations.”